Financials data is unavailable for this security.
View more
Year on year Thermo Fisher Scientific Inc 's revenues fell -4.58% from 44.92bn to 42.86bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 6.95bn to 6.00bn, a -13.74% decrease.
| Gross margin | 40.76% |
|---|---|
| Net profit margin | 14.79% |
| Operating margin | 17.01% |
| Return on assets | 6.50% |
|---|---|
| Return on equity | 13.65% |
| Return on investment | 7.66% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Thermo Fisher Scientific Inc fell by 440.00m. However, the company earned 8.41bn from its operations for a Cash Flow Margin of 19.61%. In addition the company used 5.14bn on investing activities and also paid 3.62bn in financing cash flows.
| Cash flow per share | 24.84 |
|---|---|
| Price/Cash flow per share | 24.36 |
| Book value per share | 124.17 |
|---|---|
| Tangible book value per share | -31.23 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.72 |
|---|---|
| Quick ratio | 1.37 |
| Total debt/total equity | 0.7465 |
|---|---|
| Total debt/total capital | 0.4269 |
More ▼
Growth rates in USD
Year on year, growth in dividends per share increased 16.38% while earnings per share excluding extraordinary items fell by -12.41%. The positive trend in dividend payments is noteworthy since very few companies in the Medical Equipment & Supplies industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 0.21% |
|---|---|
| Div growth rate (5 year) | 15.39% |
| Payout ratio (TTM) | 9.13% |
| EPS growth(5 years) | 15.48 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 10.15 |
More ▼
